Pharmacy Refrigerator 150L Glass Door DigiLock - EACH

RLDG0519DIGLOCK

Pharmacy Refrigerator 150L Glass Door DigiLock - EACH

3869.02 €

RLDG0519

Pharmacy Refrigerator 150L Glass Door - EACH

3338.48 €

RLDF0519DIGLOCK

Pharmacy Refrigerator 150L DigiLock - EACH

3214.95 €

EL-1611-051

Etanercept (Enbrel) Pharmacokinetic ELISA

Etanercept (trade name Enbrel®) is a protein drug used to treat autoimmune diseases by adsorbing tumor necrosis factor (TNF; a soluble inflammatory cytokine). Etanercept is a fusion protein produced through expression of recombinant DNA by linking the extracellular ligand-binding portion of TNFRSF1B to the Fc component of human immunoglobulin G1 (IgG1). It reduces the effect of naturally present TNF, functioning as a decoy receptor that binds to TNF. Etanercept is indicated for the treatment of moderate to severe rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, and moderately to severely active polyarticular juvenile idiopathic arthritis. Serum concentration of Enbrel® may predict some clinical outcome during maintenance therapy. The Etanercept ELISA kit is designed to measure free Etanercept with high specificity and sensitivity . This assay employs the sandwich enzyme immunoassay technique. A precoated anti-Etanercept 96 well plate is provided. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Etanercept present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Etanercept present in test samples and the concentration is calculated from the standard series.

1211.24 €

EL-1611-152

Omalizumab (Xolair) Pharmacokinetic ELISA

Omalizumab (Xolair®) is a recombinant DNA-derived humanized IgG1κ monoclonal antibody that binds human immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma and Chronic Idiopathic Urticaria (CIU). Omalizumab inhibits the binding of IgE to IgE receptor (FcεRI) on the surface of mast cells and basophils thereby limiting the release of mediators of the allergic response from the FcεRI bearing cells. The Omalizumab ELISA kit is designed to measure free Omalizumab with high specificity and sensitivity . This assay employs the sandwich enzyme immunoassay technique. A precoated anti-Omalizumab 96 well plate is provided. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Omalizumab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Omalizumab present in test samples and the concentration is calculated from the standard series.

1211.24 €

EL-1611-181

Rituximab (Rituxan) Pharmacokinetic ELISA

Rituximab is a chimeric monoclonal antibody used in the treatment of diseases characterized by abnormal or excessive B cells. Rituximab targets CD20, which is expressed on the surface of B cells, to induce apoptosis in B cells and is used in the treatment of leukemias and lymphomas, some autoimmune disorders, and organ transplant. A quantitative method for Rituximab has been developed and optimized for pharmacokinetic assessment of samples. The Rituximab ELISA kit is designed to measure free Rituximab with high specificity and sensitivity . This assay employs the sandwich enzyme immunoassay technique. A precoated anti-Rituximab 96 well plate is provided. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Rituximab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Rituximab present in test samples and the concentration is calculated from the standard series.

1211.24 €